Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase II Study to Evaluate Efficacy and Safety of Weekly Paclitaxel (BMS-181339)in Patients With Advanced or Recurrent Esophageal Cancer. This Study is an Extension Study for Japanese Registration Only.

NCT00344552 is registered in ClinicalTrials.gov with Bristol-Myers Squibb as lead sponsor.

NCT NCT00344552
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00344552 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase II Study to Evaluate Efficacy and Safety of Weekly Paclitaxel (BMS-181339)in Patients With Advanced or Recurrent Esophageal Cancer. This Study is an Extension Study for Japanese Registration Only.
Lead sponsor
Bristol-Myers Squibb
Phase
Phase 2
Overall status
Completed
Start date
June 30, 2006
Completion date
March 31, 2008
Enrollment
53 (actual)
Sites
12

Conditions

As the registry lists them; a condition with its own page is linked.

esophageal cancer